{"id":395596,"date":"2023-12-22T20:20:38","date_gmt":"2023-12-23T01:20:38","guid":{"rendered":"https:\/\/platohealth.ai\/pacira-names-lee-ceo-hastings-chair\/"},"modified":"2023-12-24T16:39:06","modified_gmt":"2023-12-24T21:39:06","slug":"pacira-names-lee-ceo-hastings-chair","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/pacira-names-lee-ceo-hastings-chair\/","title":{"rendered":"Pacira names Lee CEO, Hastings chair","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"

ARTICLE | Management Tracks<\/p>\n

\n
\n
\n

Plus: CRISPR\u2019s CMO to depart and a new CFO for Alterity<\/h2>\n

\n By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst<\/span><\/span>\n<\/p>\n

December 23, 2023 1:20 AM UTC<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/span><\/span><\/div>\n

Pacira BioSciences Inc.<\/a> <\/b>(NASDAQ:PCRX) name<\/span>d Frank Lee CEO and a director and Paul Hastings chair, both effective Jan. 2 \u2014 the day after Chairman and CEO David Stack is set to retire.  Lee was CEO and member of the board of Forma Therapeutics Inc.; Hastings, who joined Pacira\u2019s board in 20<\/span>11, is CEO of Nkarta Inc. (NASDAQ:NKTX).<\/p>\n

CRISPR Therapeutics AG<\/a><\/b> (NASDAQ:CRSP) disclo<\/span>sed in an SEC filing the departure of CMO Phuong Khanh Morrow, effective Jan. 26. Morrow joined CRISP<\/span>R in May 2022. The departure comes days after FDA approved<\/a> the company\u2019s Casgevy exagamglogene autotemcel, the first CRISPR-based gene editing therapy. <\/span>…<\/p>\n